KDOQI (Kidney Disease Outcomes Quality Initiative)

NKF KDOQI GUIDELINES

Executive Summaries | Anemia | Hemodialysis | Peritoneal Dialysis
Vascular Access | Nutrition | CKD 2002 | Dyslipidemias | History of KDOQI

 

KDOQI Clinical Practice Guidelines for Managing Dyslipidemias in Chronic Kidney Disease


Tables

Table 1. Definitions of Some Terms Used in These Guidelines

Table 2. Stages of Chronic Kidney Disease

Table 3. Dyslipidemias as Defined in the Adult Treatment Panel III Guidelines

Table 4. Some Government-Sponsored Web Sites With Information Useful in Risk Factor Management

Table 5. Key Features of the NKF-KDOQI Guidelines That Differ From Those of the National Cholesterol Education Program Adult Treatment Panel III

Table 6. Key Features of the NKF-KDOQI Guidelines That Differ From Those of the National Cholesterol Expert Panel on Children

Table 7. Rating the Strength of Recommendations

Table 8. Rating the Strength of Evidence

Table 9. Exclusion of CKD Patients in Some Recent, Large, Pivotal, Lipid-Lowering Trials

Table 10. Associations Between Dyslipidemias and Cardiovascular Disease in Hemodialysis Patients

Table 11. Associations Between Dyslipidemias and Cardiovascular Disease in Peritoneal Dialysis Patients

Table 12. Associations Between Dyslipidemias and Cardiovascular Disease in Kidney Transplant Recipients

Table 13. Relationship Between Dyslipidemias and Kidney Disease Progression

Table 14. The Prevalence of Dyslipidemias in Adults

Table 15. The Prevalence of Dyslipidemias in Children and Adolescents

Table 16. Prevalence of Dyslipidemias Among 1,047 Hemodialysis Patients

Table 17. Prevalence of Dyslipidemias Among 317 Peritoneal Dialysis Patients

Table 18. Serum Total Cholesterol Levels in U.S. Children and Adolescents

Table 19. Serum LDL Levels in U.S. Children and Adolescents

Table 20. Serum HDL Levels in U.S. Children and Adolescents

Table 21. Serum Triglycerides in U.S. Children and Adolescents

Table 22. Transient Effects of Some Acute Conditions on Lipid Levels

Table 23. Randomized Trials Evaluating the Effects of Immunosuppressive Agents on Dyslipidemias After Kidney Transplantation

Table 24. Secondary Causes of Dyslipidemias

Table 25. The Management of Dyslipidemias in Adults With Chronic Kidney Disease

Table 26. Therapeutic Lifestyle Changes (TLC) for Adults With Chronic Kidney Disease

Table 27. Randomized Trials Evaluating the Treatment of Dyslipidemias in Hemodialysis Patients

Table 28. Randomized Trials Evaluating the Treatment of Dyslipidemias in Peritoneal Dialysis Patients

Table 29. Randomized Trials Evaluating the Treatment of Dyslipidemia in Kidney Transplant Recipients

Table 30. Lipid-Lowering Medication Dose Adjustments for Reduced Kidney Function

Table 31. Recommended Daily Statin Dose Ranges

Table 32. Effects of Cyclosporine on Blood Levels of Statins in Kidney Transplant Recipients

Table 33. Effects of the Macrolide Antibiotic Erythromycin on Blood Levels of Statins in Normal Individuals

Table 34. Effects of Azole Antifungal Agents on Blood Levels of Statins in Normal Individuals

Table 35. Effects of Calcium-Channel Blockers on Blood Levels of Statins in Normal Individuals

Table 36. Agents That May Alter Statin Blood Levels

Table 37. The Effects of Fibrates on Blood Levels of Statins in Normal Individuals

Table 38. Bile Acid Sequestrant Dose

Table 39. Relative Effect of Different Immunosuppressive Agents on Cardiovascular Disease Risk Factors After Kidney Transplantation

Table 40. Maximum Doses of Fibrates in Patients With Reduced Kidney Function

Table 41. Nicotinic Acid Dose

Table 42. Intervention Trials That Are Needed in Patients With Chronic Kidney Disease

Table 43. Example of Format for Evidence Tables for Cardiovascular Risk

Table 44. Example of Format for Evidence Tables for Treatment Effect

Table 45. Format for Guidelines

Table 46. Dietary Modifications That May Be Appropriate for Adults With Chronic Kidney Disease

Table 47. Nutritional Characteristics of Some Protein-Source Food Items

Table 48. Margarines Containing Plant Sterol/Stanol Esters

Table 49. Contents of Some Commercially Available Cereals High in Fiber

Table 50. Contents of Some Fruits High in Fiber

Table 51. Contents of Some Vegetables High in Fiber

Table 52. Contents of Some Breads High in Fiber

Table 53. The Electrolyte Content of Some Commonly Used Fiber Supplements


2003 National Kidney Foundation, Inc.